The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Romidepsin plus lenalidomide for patients with previously untreated PTCL
Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, discusses the findings of a multicenter Phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL). Novel agents such as the HDAC inhibitor romidepsin and lenalidomide have demonstrated clinical activity in patients with relapsed/refractory PTCL; in combination, this study reported an objective response rate of 75% and an estimated 1-year progression-free survival of 54.3%, demonstrating that a chemotherapy-free combination of romidepsin and lenalidomide is feasible and effective as initial therapy for PTCL patients who are not candidates for cytotoxic chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
